Waylivra
E133691
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
All labels observed (2)
| Label | Occurrences |
|---|---|
| volanesorsen | 3 |
| Waylivra canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1169604 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Waylivra Context triple: [Ionis Pharmaceuticals, notableProduct, Waylivra]
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Versonnex
Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Waylivra Target entity description: Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Versonnex
Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
antisense oligonucleotide therapy
ⓘ
medication ⓘ prescription drug ⓘ |
| administrationFrequency | weekly injection (typical maintenance) ⓘ |
| affects | triglyceride levels in blood ⓘ |
| approvalYear | 2019 (EU) ⓘ |
| belongsToRegimen | long-term management of familial chylomicronemia syndrome ⓘ |
| commonAdverseEffect |
flu-like symptoms
ⓘ
injection site reactions ⓘ nausea ⓘ |
| contraindication |
hypersensitivity to volanesorsen
ⓘ
severe thrombocytopenia ⓘ |
| developedBy | Ionis Pharmaceuticals ⓘ |
| dosageForm | solution for injection ⓘ |
| drugClass | antisense oligonucleotide ⓘ |
| hasActiveIngredient |
volanesorsen
ⓘ
linked to:
Waylivra
|
| hasBlackBoxWarning | thrombocytopenia ⓘ |
| hasGenericName |
volanesorsen
ⓘ
linked to:
Waylivra
|
| hasOrphanDrugDesignation | familial chylomicronemia syndrome ⓘ |
| indicatedFor | adult patients with familial chylomicronemia syndrome ⓘ |
| indication | familial chylomicronemia syndrome ⓘ |
| indicationType | orphan disease treatment ⓘ |
| initialDosingRegimen | more frequent injections during loading phase ⓘ |
| isBrandOf |
volanesorsen
ⓘ
linked to:
Waylivra
|
| marketingAuthorisationHolder | Ionis Pharmaceuticals ⓘ |
| mechanismOfAction | inhibition of apolipoprotein C-III synthesis ⓘ |
| monitoringParameter |
fasting triglyceride levels
ⓘ
liver function tests ⓘ platelet counts ⓘ |
| pharmacologicalClass | antisense inhibitor of apolipoprotein C-III ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| reduces |
apolipoprotein C-III levels
ⓘ
chylomicrons ⓘ plasma triglycerides ⓘ |
| reducesRiskOf | pancreatitis in FCS patients ⓘ |
| regulatoryStatus |
approved in European Union
ⓘ
withdrawn application in United States ⓘ |
| requires |
dietary fat restriction as adjunct therapy
ⓘ
regular platelet monitoring ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| seriousAdverseEffect |
bleeding risk
ⓘ
thrombocytopenia ⓘ |
| targets | APOC3 mRNA ⓘ |
| therapeuticArea |
metabolic diseases
ⓘ
rare lipid disorders ⓘ |
| treats | familial chylomicronemia syndrome ⓘ |
| usedFor | reduction of triglyceride levels ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Waylivra Description of subject: Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Waylivra
linked to: Waylivra